Q-omics provides the consensus-scored NCAPG profile across patient tissues and cancer cell-line models. NCAPG expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NCAPG is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, NCAPG protein abundance shows 33,177 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where NCAPG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCAPG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCAPG survival associations across molecular data types. NCAPG RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCAPG RNA expression–survival associations across cancer types. High NCAPG expression shows unfavorable associations in KIRP, MESO, ACC, LIHC, KICH and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for NCAPG RNA expression.
This table summarizes NCAPG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for NCAPG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCAPG shows higher tumor expression in HNSC, LUAD, BLCA, KIRP, KIRC and STAD. The HNSC box plot shows higher NCAPG RNA expression in tumor versus normal tissue (log2 FC = +1.839, t-test p < 0.001).
This table shows molecular features associated with NCAPG in patient tissues and cancer cell lines. In patient samples, NCAPG shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NCAPG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
